Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients

Transplantation

Volumn 62, Issue 5, 1996, Pages 666-672

  Langman, Loralie J ^a   LeGatt, Donald F ^a   Halloran, Phillip F ^a   Yatscoff, Randall W ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GUANOSINE DIPHOSPHATE; GUANOSINE PHOSPHATE; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; PREDNISONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG MIXTURE; DRUG MONITORING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PURINE SYNTHESIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0029812955     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199609150-00022     Document Type: Article

References (31)

1. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability of mycophenolic acid through amino acid derivatization. Pharmacol Res 1990; 7: 161.
2. Eugui E, Mirkovich A, Allison A. Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in mice. Scand J Immunol 1991; 33: 175.
3. Eugui E, Almquist S, Muller G, Allison A. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161.
4. Sweeney M, Huffman D, Esterman M. Metabolism and biochemistry of mycophenolic acid. Cancer Res 1972; 32: 1803.
5. Wu JC. Mycophenolate mofetil: molecular mechanism of action. Perspect Drug Discov Design 1994; 2: 185.
6. Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanism of action of mycophenolic acid. Ann N Y Acad Sci 1993; 696: 63.
7. Platz KP, Sollinger HW, Hallet DA, Echhoff DE, Eugui EM, Allison AC. RS-61443: a new potent immunosuppressive agent. Transplantation 1991; 51: 27.
8. Hao L, Lafferty KJ, Allison AC, Eugui EM. RS-16443 allows islet allografting and specific tolerance induction in adult mice. Transplant Proc 1990; 22: 876.
9. Morris RE, Wang J. Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinoethyl ester of mycophenolic acid (RS-61443) in recipients of heart allografts. Transplant Proc 1991; 23: 493.
10. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993; 56: 75.
11. Skoloski JA, Blair OC, Sartorelli AC. Alterations in glycoprotein and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of 5′-monophosphate dehydrogenase. Cancer Res 1986; 46: 2314.
12. Sollinger HW, Beizer OF, Deoerhoi MH, et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Am Surg 1993; 216: 513.
13. Sollinger HW, for the United States Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
14. Sollinger HW, Deoerhoi MH, Belzer OF, Diethelm AG, Kauffman RS. RS-61443: a phase I clinical trial and pilot rescue study. Transplantation 1992; 53: 428.
15. Yatscoff RW, Keenan R, LeGatt DF. Single-dose pharmacokinetics of the new immunosuppressant RS-61443 in the rabbit. Ther Drug Monit 1993; 15: 400.
16. Shaw L, Sollinger HW, Halloran PF, et al. Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit 1995; 17: 690.
17. Batiuk TD, Pazderka F, Halloran PF. Calcineurin is only partially inhibited in leucocytes of cyclosporine-treated patients. Transplantation 1995; 59: 1400.
18. Langman LJ, LeGatt DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 1995; 41: 295.
19. Langman LJ, Shapiro AJ, Lakey RT, LeGatt DF, Kneteman NM, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid induced immunosuppression by measurement of IMP dehydrogenase in a canine model. Transplantation 1996; 61: 87.
20. 2-cyclosporin) in blood and plasma. Clin Chem 1993; 39: 213.
21. Yatscoff R, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation 1993; 56: 1202.
22. Scrimgeour KG. Chemistry and control of enzyme reactions. New York: Academic Press, 1977: 99.
23. Schweinsberg PD, Loo TL. Simultaneous analysis of ATP, ADP, AMP and other purines in human erythrocytes by high-performance liquid chromatography. J Chromatogr 1979; 181: 103.
24. Liu J, Farmer JD, Lane WS, Freidman J, Weissman I, Schriber SC. Calcineurin is a common target of cyclophillin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807.
25. Frumen Da, Hee CB, Bierer B, Burchold SJ. Calcineurin phosphatase activity in T-lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 89: 3686.
26. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995; 41: 1011.
27. Deleted in proof.
28. Deleted in proof.
29. Dayton JS, Turka LA, Thompson CB, Mitchell BS. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1992; 41: 671.
30. Mitchell S, Dayton JS, Turka LA, Thompson CB. IMP dehydro-genase inhibitors as immunomodulators. Ann N Y Acad Sci 1993; 685: 217.
31. Natsumeda Y, Carr SF. Human type I and II IMP dehydrogenase as drug targets. Ann N Y Acad Sci 1993; 696: 88.